Research programme: lung disorder therapeutics - Parion Sciences
Latest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Parion Sciences
- Class Antiasthmatics; Antibronchitics; Antifibrotics; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Idiopathic pulmonary fibrosis; Viral infections
- Research Asthma
Most Recent Events
- 12 Oct 2023 Preclinical trials in Bronchiectasis in USA (unspecified route), prior to October 2023 (Parion Sciences pipeline, October 2023)
- 11 Oct 2023 Early research in Asthma in USA (unspecified route), prior to October 2023 (Parion Sciences pipeline, October 2023)
- 11 Oct 2023 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route), prior to October 2023 (Parion Sciences pipeline, October 2023)